"The system being developed by AMPLITUDE will be the first device to deliver a label-free procedure. This means we can avoid using ﬂuorophores and their phototoxic effects which can sometimes damage cells.
"A reduction in the phototoxicity during autofluorescence imaging will minimise cell damage"
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
The system works by using infrared light to visualise deep inside the tissue, allowing scientists to peer into 'biological windows' or infrared areas where light penetration increases in depth.
"The so-called 'third biological window' - a range of 1550–1870 nanometres - has not yet been extensively investigated.
"While it is possible to investigate this range at present, we would need a Supercontinuum laser source, which is prohibitively expensive.
"The new lasers that will be developed by AMPLITUDE will allow us to explore this wavelength range with compact and cost-effective systems," said Dr Gumenyuk.
The project is coordinated by Tampere University (Finland) and comprises several specialists from across Europe, including the Aston Insitute of Photonic Technologies—AIPT (UK), Modus Research and Innovation Ltd. (UK), Consiglio Nazionale delle Ricerche—CNR (Italy), University of Milan-Bicocca, and University of Florence (Italy), Institute of Photonic Sciences—ICFO (Spain), Ampliconyx Oy (Finland), Femtonics Ltd. (Hungary), HC Photonics (Taiwan), and LEONI Fiber Optics GmbH (Germany).
Photonics21 is the European Technology Platform (ETP) for photonics, a technology encompassing all of the products and processes around the emission, manipulation and detection of light. Photonics is integral to a wide range of industries that include the medical, healthcare, transport, manufacturing, and telecommunications sectors.
"Photonics21" was set up in December 2005 to bring the community of photonics researchers and industries together. The European Commission defined photonics as one of five European Key Enabling Technologies (KET's) in September 2009. Shortly after, the European Research & Innovation Program "Horizon 2020" invited Photonics21 to become a "Public-Private Partnership" (PPP). The "Photonics 21 Association", a legal entity under Belgium law, became the private contract partner in November 2013 in a Public-Private Partnership (PPP) in conjunction with the EU Commission.
Today Photonics21 represents more than 3000 personal members from across Europe and abroad. Our members are experts in the photonics industry, research organisations and universities who actively engage with us to develop a joint photonics strategy for future research and innovation in Europe.